Innovatus Capital Partners

Imperative Care, Inc. is a medical technology company based in Campbell, California, established in 2015. The company specializes in developing innovative solutions aimed at enhancing the diagnosis, treatment, and rehabilitation of stroke patients. Its primary offerings include the Large Distal Platform, a catheter designed to facilitate access to treatment sites for both ischemic and hemorrhagic stroke procedures, and the ZOOM Aspiration System, which works in conjunction with the Large Distal Platform to provide a comprehensive solution for clot removal across various occlusion sizes. By focusing on improving the speed and effectiveness of acute stroke treatment, Imperative Care aims to address significant unmet needs in stroke care, ultimately providing patients with better prospects for recovery.

Celcuity Inc. is a clinical-stage biotechnology company based in Minneapolis, Minnesota, focusing on cancer diagnosis and treatment. The company utilizes its CELsignia diagnostic platform, which analyzes living tumor cells to identify specific cellular processes that drive individual cancers. This innovative approach enables the discovery of new cancer sub-types that traditional molecular diagnostics may miss. Celcuity is developing diagnostic tests, including the CELsignia HSF test for HER2-negative breast cancer and the CELsignia MP test for various cancers, such as breast, lung, colon, ovarian, kidney, and bladder. By translating these discoveries into companion diagnostics, Celcuity aims to enhance therapeutic options for cancer patients and improve treatment outcomes, while also aiding pharmaceutical companies in defining targeted therapy patient populations more accurately. Founded in 2011, Celcuity is committed to advancing oncology through precise diagnostic and therapeutic innovations.

Codexis, Inc. is an industrial biotechnology company that specializes in the discovery, development, and commercialization of protein catalysts for pharmaceutical and chemical production through biocatalysis. Founded in 2002 and headquartered in Redwood City, California, Codexis utilizes its proprietary CodeEvolver directed evolution technology platform to create enzyme optimization solutions that enhance process development from research to manufacturing. The company offers a range of products and services, including biocatalysts, enzyme screening, and protein engineering services, which are utilized by over 50 pharmaceutical firms globally. Codexis generates the majority of its revenue through product sales and also licenses its CodeEvolver technology to enable pharmaceutical companies to engineer enzymes for their own production needs. Its customer base spans various markets, including the United States, Europe, and Asia, contributing to the company's growth in the biotechnology sector.

JenaValve Technology, Inc. is a medical device company specializing in the design, development, and manufacturing of transcatheter aortic valve replacement (TAVR) systems for patients with severe aortic regurgitation and aortic stenosis. Founded in 2006 and headquartered in Irvine, California, with additional locations in Munich, Germany, and Leeds, United Kingdom, the company focuses on providing innovative solutions for high-risk patients who may not be suitable candidates for traditional surgical aortic valve replacement. The company's flagship product, the Trilogy™ Heart Valve System, received CE Mark approval in May 2021 and is notable for its dual-disease treatment capabilities. JenaValve's TAVR systems feature a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame, designed to engage with the native valve structures for optimal performance. The company has also received Breakthrough Device Designation from the U.S. Food and Drug Administration to facilitate the review of its pivotal trial for the Trilogy Heart Valve System in the United States.

MDxHealth is a molecular diagnostics company focused on developing and commercializing advanced epigenetic tests to assist in the detection and treatment of cancer. The company's product portfolio includes ConfirmMDx, a prostate cancer test aimed at addressing false-negative biopsy concerns; SelectMDx, which guides repeat biopsies for prostate cancer; AssureMDx, a noninvasive liquid biopsy test for bladder cancer; and PredictMDx for Glioblastoma, a tissue methylation test that aids in treatment decisions for brain cancer. Established in 2003 and headquartered in Irvine, California, with additional offices in Belgium and the Netherlands, MDxHealth leverages proprietary genomic and epigenetic technologies to provide actionable diagnostic information. The company's revenue is generated through clinical laboratory services and out-licensing of its patented DNA methylation platform and biomarkers, serving markets primarily in the United States and Europe.

Syapse, Inc. is a technology company that specializes in precision medicine through its innovative software platform, which aggregates and analyzes clinical, molecular, treatment, and outcomes data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse aims to enhance healthcare by providing actionable insights that support data-driven decision-making in precision oncology. The company operates the Syapse Learning Health Network, a global network that enables health systems and life sciences collaborators to share real-world cancer data. This network empowers healthcare organizations to collaborate effectively, ensuring that oncologists and decision-makers have access to comprehensive patient insights at the point of care, ultimately driving improved outcomes for cancer patients. Syapse has established strategic partnerships, including a collaboration with Pfizer, to further its mission of delivering personalized care based on robust real-world evidence.

Eiger BioPharmaceuticals is a late-stage biopharmaceutical company headquartered in Palo Alto, California, specializing in the development of targeted therapies for rare and ultra-rare diseases. The company's lead product candidate, Lonafarnib, is an orally bioavailable small molecule currently in Phase 3 clinical trials for the treatment of hepatitis delta virus (HDV) infection, a life-threatening condition with significant unmet medical needs. Eiger's pipeline also includes Lambda, which is being evaluated in Phase 2 trials for HDV treatment, and Lonafarnib is being explored for its potential use in treating progeria and progeroid laminopathies. Additionally, Avexitide, which has completed Phase 2 trials for post-bariatric hypoglycemia, is also undergoing clinical evaluation for congenital hyperinsulinism. Eiger's strategic focus is on efficient drug development to deliver safe and effective therapies to patients suffering from these serious conditions.

Eiger BioPharmaceuticals is a late-stage biopharmaceutical company headquartered in Palo Alto, California, specializing in the development of targeted therapies for rare and ultra-rare diseases. The company's lead product candidate, Lonafarnib, is an orally bioavailable small molecule currently in Phase 3 clinical trials for the treatment of hepatitis delta virus (HDV) infection, a life-threatening condition with significant unmet medical needs. Eiger's pipeline also includes Lambda, which is being evaluated in Phase 2 trials for HDV treatment, and Lonafarnib is being explored for its potential use in treating progeria and progeroid laminopathies. Additionally, Avexitide, which has completed Phase 2 trials for post-bariatric hypoglycemia, is also undergoing clinical evaluation for congenital hyperinsulinism. Eiger's strategic focus is on efficient drug development to deliver safe and effective therapies to patients suffering from these serious conditions.

DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.

Apollo Endosurgery, Inc. is a medical technology company based in Austin, Texas, specializing in the design, development, and commercialization of innovative medical devices for gastrointestinal health. Founded in 2005, the company focuses on advancing therapeutic endoscopy as a less invasive alternative to traditional surgical procedures, thereby reducing complication rates and overall healthcare costs. Its product portfolio includes the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which enable physicians to place full-thickness sutures and secure tissue approximation through flexible endoscopy. Additionally, Apollo offers the X-Tack Endoscopic HeliX Tacking System and the Orbera Intragastric Balloon, which aids in weight management by reducing stomach capacity. The company's devices cater to gastroenterologists and bariatric surgeons, addressing various gastrointestinal conditions such as acute perforations and chronic fistulas. Apollo Endosurgery's commitment to innovation is rooted in the collaborative efforts of a distinguished group of gastroenterologists and surgeons who aimed to enhance the field of therapeutic endoscopy.

Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. The company specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. Its flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on individualized peripheral nerve stimulation to enhance patient outcomes. In addition to its work on essential tremor, the company is also developing therapies for conditions such as Parkinson's disease, as well as exploring applications in psychiatry, cardiology, and autoimmune disorders.

Geneoscopy, LLC is a diagnostics company based in Saint Louis, Missouri, that specializes in non-invasive colorectal cancer screening and gastrointestinal disease management. Founded in 2015, Geneoscopy has developed a platform technology that utilizes stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the downstream effects of cancer-causing DNA mutations. The company's diagnostic test aims to improve compliance with colorectal cancer screening, facilitate early-stage detection of neoplasms, and ultimately reduce morbidity and mortality associated with the disease. Additionally, Geneoscopy is exploring other applications of its technology for various gastrointestinal conditions, aiming to provide reliable alternatives to traditional invasive procedures like colonoscopy.

Exagen Inc. is a commercial-stage diagnostics company focused on developing and commercializing innovative testing products for autoimmune and autoimmune-related diseases. Headquartered in Vista, California, Exagen utilizes its proprietary Cell-Bound Complement Activation Products technology to enhance diagnostic care for conditions like systemic lupus erythematosus and rheumatoid arthritis. The company offers a diverse portfolio of testing products under its AVISE brand, including AVISE CTD for differential diagnosis of connective tissue diseases, AVISE Lupus for monitoring complement system activation, and multiple panels for assessing various autoimmune markers. These products facilitate timely diagnosis and effective therapeutic interventions, enabling rheumatologists to improve patient care. Since its founding in 2002, Exagen has remained committed to addressing the needs of patients suffering from chronic autoimmune diseases.

Spacial is a San Francisco based company building accessory dwelling units for homeowner's backyards. The ADUs are beautiful, spacious and airy, and we utilize offsite construction increase speed to installation and decrease costs to homeowners, while delivering a home built to the same standard as their primary residence.

Imperative Care, Inc. is a medical technology company based in Campbell, California, established in 2015. The company specializes in developing innovative solutions aimed at enhancing the diagnosis, treatment, and rehabilitation of stroke patients. Its primary offerings include the Large Distal Platform, a catheter designed to facilitate access to treatment sites for both ischemic and hemorrhagic stroke procedures, and the ZOOM Aspiration System, which works in conjunction with the Large Distal Platform to provide a comprehensive solution for clot removal across various occlusion sizes. By focusing on improving the speed and effectiveness of acute stroke treatment, Imperative Care aims to address significant unmet needs in stroke care, ultimately providing patients with better prospects for recovery.

Match Marketing Group Inc. is a Canadian activation agency based in Mississauga, specializing in shopper marketing solutions designed to inspire consumer purchases through integrated experiences. Founded in 2011, the company offers a comprehensive range of services, including insights and strategy, digital marketing, experiential marketing, merchandising, and retail solutions. By focusing on the connected shopper, Match Marketing Group aims to enhance brand value and drive demand for its clients, which include notable brands such as adidas, GoGo Squeez, Malibu Rum, Lincoln Motor Company, and Ford. The agency's goal is to create seamless interactions that reflect modern shopping behaviors, facilitating effective consumer engagement both online and offline.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

VSA Partners, Inc. is a branding and marketing services company founded in 1982, with headquarters located in Chicago, Illinois, and additional offices in New York and San Francisco. Formerly known as Vogele Stoik Associates, Inc., the company rebranded in December 1984. VSA Partners provides a range of interconnected services including strategy, digital systems, design, visual identity, corporate communications, retail design, and packaging. Its comprehensive approach is designed to enhance client engagement and facilitate effective interactions across various digital platforms. By focusing on cross-channel branding and marketing solutions, VSA Partners aims to help businesses connect with their audiences in meaningful ways.

VICIS is a Seattle-based company dedicated to advancing football helmet technology to minimize the risk of sports-related head injuries, particularly concussions. Founded in 2013, VICIS has developed the ZERO1 helmet, which achieved the highest ranking in the 2017 NFL/NFLPA Helmet Performance Testing. This innovative helmet is designed for use in the NFL, NCAA, and select high school programs, showcasing the company’s commitment to athlete safety. By integrating expertise from both medicine and engineering, VICIS aims to provide enhanced protection for athletes of all ages, ultimately improving their performance and well-being on the field.

Akoya Biosciences is a spatial biology company offering the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has two industry-leading platforms that empower investigators and researchers to gain a deeper understanding of complex diseases such as cancer, and autoimmune or neurological disorders. The CODEX system is the only benchtop platform that can efficiently quantify more than 40 biomarkers and is ideally suited for biomarker discovery. The Phenoptics platform is the only end-to-end multiplexed immunofluorescence solution with the robustness and high throughput necessary for translational research and clinical trials.

ConforMIS is a United States-based medical technology company that specializes in developing, manufacturing, and selling joint replacement implants and instruments tailored to each patient's unique anatomy. Utilizing its proprietary iFit Image-to-Implant technology platform, ConforMIS creates personalized knee and hip implants, as well as single-use surgical instruments. The company's offerings include various partial and total knee replacement implants, such as the iTotal CR, iTotal PS, iDuo, and iUni. These products are delivered directly to hospitals and ambulatory surgical centers, ensuring that each implant is individually sized and shaped for optimal fit.

ConforMIS is a United States-based medical technology company that specializes in developing, manufacturing, and selling joint replacement implants and instruments tailored to each patient's unique anatomy. Utilizing its proprietary iFit Image-to-Implant technology platform, ConforMIS creates personalized knee and hip implants, as well as single-use surgical instruments. The company's offerings include various partial and total knee replacement implants, such as the iTotal CR, iTotal PS, iDuo, and iUni. These products are delivered directly to hospitals and ambulatory surgical centers, ensuring that each implant is individually sized and shaped for optimal fit.

DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

Exagen Inc. is a commercial-stage diagnostics company focused on developing and commercializing innovative testing products for autoimmune and autoimmune-related diseases. Headquartered in Vista, California, Exagen utilizes its proprietary Cell-Bound Complement Activation Products technology to enhance diagnostic care for conditions like systemic lupus erythematosus and rheumatoid arthritis. The company offers a diverse portfolio of testing products under its AVISE brand, including AVISE CTD for differential diagnosis of connective tissue diseases, AVISE Lupus for monitoring complement system activation, and multiple panels for assessing various autoimmune markers. These products facilitate timely diagnosis and effective therapeutic interventions, enabling rheumatologists to improve patient care. Since its founding in 2002, Exagen has remained committed to addressing the needs of patients suffering from chronic autoimmune diseases.